Literature DB >> 9706141

Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer.

D W Denham1, M G Franz, W Denham, E E Zervos, W R Gower, A S Rosemurgy, J Norman.   

Abstract

BACKGROUND: The level of expression of the alpha isoform of protein kinase C (PKC-alpha) has been shown to correlate inversely with the pathologic differentiation of human pancreatic cancers.
METHODS: We stably transfected a moderately differentiated pancreatic cell line (HPAC) to overexpress PKC-alpha and examined the survival rates compared with parent HPAC according to an orthotopic model. Next we used a PKC-alpha antisense oligonucleotide specifically to down-regulate this isoform in vitro and examine the effect of treatment in vivo again according to the orthotopic model.
RESULTS: Animals implanted with the overexpressing cell line had a mortality rate almost twice that of those implanted with the parent cell line (P < .01). Treatment with antisense oligonucleotide in increasing concentrations down-regulated PKC-alpha mRNA by Northern blot analysis and reverse transcriptase-polymerase chain reaction. Animals treated with antisense oligonucleotide after orthotopic implantation of pancreatic cancer cells survived statistically longer than those treated with vehicle alone (P = .005). Treatment with a scrambled oligonucleotide also conferred a survival benefit compared with vehicle alone (P < .01).
CONCLUSIONS: Tumorigenicity of pancreatic cancer is related directly to PKC-alpha expression in vivo as demonstrated by decreased survival when overexpressed. PKC-alpha expression can be down-regulated directly (antisense) and indirectly (scrambled) in vitro, which subsequently confers a dramatic survival benefit in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706141

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

Review 1.  Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.

Authors:  Daisuke Kyuno; Hiroshi Yamaguchi; Tatsuya Ito; Tsuyoshi Kono; Yasutoshi Kimura; Masafumi Imamura; Takumi Konno; Koichi Hirata; Norimasa Sawada; Takashi Kojima
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Role of protein kinase D signaling in pancreatic cancer.

Authors:  Sushovan Guha; Suebpong Tanasanvimon; James Sinnett-Smith; Enrique Rozengurt
Journal:  Biochem Pharmacol       Date:  2010-07-16       Impact factor: 5.858

Review 3.  Novel protein kinases in pancreatic cell growth and cancer.

Authors:  Thomas Seufferlein
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 4.  Protein kinase C isoforms in the normal pancreas and in pancreatic disease.

Authors:  Alicia K Fleming; Peter Storz
Journal:  Cell Signal       Date:  2017-08-18       Impact factor: 4.315

Review 5.  Targeting protein kinase C subtypes in pancreatic cancer.

Authors:  Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2015-01-20       Impact factor: 4.512

Review 6.  The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis.

Authors:  Pramod Mallikarjuna; Yang Zhou; Maréne Landström
Journal:  Biomolecules       Date:  2022-04-25

Review 7.  The complexities of PKCα signaling in cancer.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Adv Biol Regul       Date:  2020-11-23

8.  Angiotropic metastatic malignant melanoma in a canine mammary gland.

Authors:  Hai Jie Yang; Eun-Mi Lee; Ah-Young Kim; Eun-Joo Lee; Il-Hwa Hong; Sung-Oh Huh; Kyu-Shik Jeong
Journal:  Lab Anim Res       Date:  2011-12-19

9.  Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.

Authors:  Chao He; Jian Sun; Chao Liu; Yuhang Jiang; Yongqiang Hao
Journal:  Clin Epigenetics       Date:  2019-01-16       Impact factor: 6.551

Review 10.  Tight junctions in human pancreatic duct epithelial cells.

Authors:  Takashi Kojima; Hiroshi Yamaguchi; Tatsuya Ito; Daisuke Kyuno; Tsuyoshi Kono; Takumi Konno; Norimasa Sawada
Journal:  Tissue Barriers       Date:  2013-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.